Oncology Peer Review On-The-Go: Ofer Sharon, MD, Discusses OncoHost and PROPHETIC Trial for NSCLC

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.

Kira MacDougall, MD, and Muhammad Rafay Khan Niazi, MD, spoke with CancerNetwork® about their research into the significance of peripheral blood biomarkers of response to immunotherapy in non–small cell lung cancer published in the journal ONCOLOGY®.

Final analyses for pathologic response appear consistent with previous reports from the phase 3 AEGEAN trial evaluating neoadjuvant durvalumab and chemotherapy plus adjuvant durvalumab monotherapy in resectable non–small cell lung cancer.

Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.

Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.

Pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab also appears to improve pathological responses in patients with non–small cell lung cancer.